Autolus Therapeutics (NASDAQ:AUTL) is a biopharmaceutical company focused on the development and commercialization of next-generation programmed T cell therapies for the treatment of cancer. The company's pioneering work in CAR T cell therapy, aimed at harnessing the power of patients' immune systems to combat cancer, positions it at the forefront of cell and gene therapy. Autolus Therapeutics is committed to advancing a diverse portfolio of treatment candidates, with a primary objective of delivering life-changing benefits to patients facing serious diseases. Through innovative research and strategic partnerships, the company aims to improve clinical outcomes and fundamentally alter the cancer treatment landscape.